This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Example content

CommitmentHeritageInitiativesInnovationPortfolio

Menu

Close

Information on how to access prescribing information and adverse event reporting can be found at the bottom of this page.

Leading the Way in Innovation

Scientific advances in understanding cancer, coupled with innovative treatment breakthroughs, mean that cancer care has been transformed in recent years, and more people than ever will survive the disease.1

At Pfizer, we are committed to the discovery and development of pioneering therapies that continue to improve the outlook for cancer patients. Over the past decade, we've taken bold new approaches to translate innovative scientific research into meaningful breakthrough medicines for people living with cancer. And we won't stop there.

We're striving to advance the frontiers of cancer biology to develop a new generation of cutting edge therapies, across multiple cancers and tumour types for which an unmet need exists. Each day, our scientists are working towards discovering new breakthroughs that could save lives.

Committed To Innovation

Our pipeline includes biologics, small molecules, immunotherapies and biosimilars, and is centred on exploring a multitude of approaches across many tumour types.​​​​​​​

We are focussed on the development of biologics, small molecules, immunotherapies and biosimilars, for a range of tumour types:
A Focus On Precision Immunotherapy Approaches And Targeted Therapies

We are focused on exploring genetic, phenotypic, and functional biomarkers to help guide clinical research strategies and ensure the right patients are treated with the right medicines. Our goal is to develop therapies with potentially transformational outcomes.

Specific area of interest include:​​​​​​​

  • new chemical entities (NCEs)
  • monoclonal antibodies (mAbs)
  • antibody drug conjugates
  • oncogenic drivers / cell signalling
  • anti-angiogenics
  • cancer stem cell metabolism, and epigenetics
  • bi-specifics
  • vaccines
Prescribing Information for Great Britain and Northern Ireland:
​​​​​​​

Bavencio® (avelumab) + axitinib aRCC
Bavencio®(avelumab) MCC & UC

Besponsa® (inotuzumab ozogamicin)

Mylotarg®
(gemtuzumab ozogamicin)

Ruxience®
(rituximab)

Trazimera®
(trastuzumab)

Zirabev®
(bevacizumab)​​​​​​​



​​​​​​​References:
​​​​​​​

1. Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer 2012; 107 (7):1195-202.  

PP-UNP-GBR-0760. May 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-UNP-GBR-0596. April 2022
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

​​​​​​I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

​​​​​​​*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.​​​​​​​

​​​​​​​PP-PFE-GBR-3863. November 2021​​​​​​

Yes No
You are now leaving PfizerPro  
​​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​​​​​​​​
 
You are now leaving PfizerPro  
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021​​​​​​​
 

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?